Golden has been acquired by ComplyAdvantage.Read about it here ⟶

List of PrimeVax Immuno-Oncology patents

List of PrimeVax Immuno-Oncology patents

List of Ionu Security, Inc. patents

List of Wickr patents

List of Convergent Dental patents

List of AI robotic process automation companies

List of companies in Capital Factory's investment portfolio

Patents where

Current Assignee

Name

is

PrimeVax Immuno-Oncology

	Name	Description	Patent Applicant	Current Assignee	Inventor	Patent Jurisdiction	Patent Number	Date of Patent
	‌ US Patent 11357795 Combination immunotherapies for treatment of cancer	Patent 11357795 was granted and assigned to PrimeVax Immuno-Oncology on June, 2022 by the United States Patent and Trademark Office.	PrimeVax Immuno-Oncology	PrimeVax Immuno-Oncology		United States Patent and Trademark Office	11357795	June 14, 2022
	‌ US Patent 10357553 Compositions and methods for combination therapy with dengue virus and dendritic cells	Patent 10357553 was granted and assigned to PrimeVax Immuno-Oncology on July, 2019 by the United States Patent and Trademark Office.	PrimeVax Immuno-Oncology	PrimeVax Immuno-Oncology		United States Patent and Trademark Office	10357553	July 23, 2019
	‌ US Patent 9730989 Compositions and methods for combination therapy with dengue virus and dendritic cells	Patent 9730989 was granted and assigned to PrimeVax Immuno-Oncology on August, 2017 by the United States Patent and Trademark Office.	PrimeVax Immuno-Oncology	PrimeVax Immuno-Oncology		United States Patent and Trademark Office	9730989	August 15, 2017
	‌ US Patent 10946080 Compositions and methods for combination therapy with dengue virus and dendritic cells	Patent 10946080 was granted and assigned to PrimeVax Immuno-Oncology on March, 2021 by the United States Patent and Trademark Office.	PrimeVax Immuno-Oncology	PrimeVax Immuno-Oncology		United States Patent and Trademark Office	10946080	March 16, 2021
	‌ US Patent 9849167 Compositions and methods for combination therapy with dengue virus and dendritic cells	Patent 9849167 was granted and assigned to PrimeVax Immuno-Oncology on December, 2017 by the United States Patent and Trademark Office.	PrimeVax Immuno-Oncology	PrimeVax Immuno-Oncology		United States Patent and Trademark Office	9849167	December 26, 2017
	‌ US Patent 10159727 Compositions and methods for combination therapy with dengue virus and dendritic cells	Patent 10159727 was granted and assigned to PrimeVax Immuno-Oncology on December, 2018 by the United States Patent and Trademark Office.	PrimeVax Immuno-Oncology	PrimeVax Immuno-Oncology		United States Patent and Trademark Office	10159727	December 25, 2018
	‌ US Patent 10675304 Combination immunotherapies for treatment of cancer	Patent 10675304 was granted and assigned to PrimeVax Immuno-Oncology on June, 2020 by the United States Patent and Trademark Office.	PrimeVax Immuno-Oncology	PrimeVax Immuno-Oncology		United States Patent and Trademark Office	10675304	June 9, 2020
	‌ US Patent 10765727 Compositions and methods for producing dendritic cells		PrimeVax Immuno-Oncology	PrimeVax Immuno-Oncology		United States Patent and Trademark Office	10765727	September 8, 2020
	‌ US Patent 10293038 Compositions and methods for combination therapy with dengue virus and dendritic cells	Patent 10293038 was granted and assigned to PrimeVax Immuno-Oncology on May, 2019 by the United States Patent and Trademark Office.	PrimeVax Immuno-Oncology	PrimeVax Immuno-Oncology		United States Patent and Trademark Office	10293038	May 21, 2019

9 results

0 selected

9 results

0 selected